Sandoz Executive and Leadership Team

Shivendra Singh, the Group Chief Financial Officer at Sandoz, directs the global financial architecture and capital allocation strategies for the organization. Overseeing fiscal reporting, risk management, and long-term investment planning, the Group Chief Financial Officer ensures the company maintains a robust balance sheet to support the manufacturing of generic medicines and biosimilars. This leadership role involves close collaboration with the Board to optimize capital structure and drive sustainable growth across international markets. By implementing rigorous financial controls, Shivendra Singh strengthens the operational efficiency of the entire enterprise. The Group Chief Financial Officer monitors global economic trends to mitigate volatility, ensuring the company remains a leader in the pharmaceutical sector. Through precise financial oversight, the Group Chief Financial Officer secures the resources necessary for the continued development of life-saving treatments, ultimately reinforcing the market position of the firm.

Martin Fournier, the Vice President, Finance & Chief Financial Officer at Sandoz, manages the internal financial operations and regional budgetary frameworks. Focusing on the optimization of manufacturing costs and supply chain expenditures, the Vice President, Finance & Chief Financial Officer drives profitability through disciplined resource management. This role requires constant interaction with operational leads to align departmental spending with the broader corporate mission of delivering affordable healthcare. Martin Fournier executes complex financial modeling to support the expansion of the biosimilars portfolio, ensuring that every investment yields maximum value for patients. By streamlining accounting processes and enhancing transparency, the Vice President, Finance & Chief Financial Officer provides the data-driven insights required for strategic decision-making. The Vice President, Finance & Chief Financial Officer maintains a sharp focus on cost-efficiency, which allows the company to remain competitive while scaling production capabilities across diverse therapeutic areas.

Keren Haruvi, the President, Sandoz (North America) at Sandoz, directs all commercial operations and market expansion strategies within the North American region. Overseeing the distribution of generic medicines and biosimilars, the President, Sandoz (North America) ensures that healthcare providers and patients have consistent access to affordable treatments. This leadership role involves navigating complex regulatory landscapes and building strategic partnerships with major healthcare systems. Keren Haruvi executes growth initiatives that capitalize on the increasing demand for cost-effective cardiovascular and oncology medications. By analyzing regional market trends, the President, Sandoz (North America) optimizes the supply chain to meet local needs efficiently. The President, Sandoz (North America) collaborates with global leadership to ensure that regional activities remain consistent with the overarching corporate mission. Through decisive management, the President, Sandoz (North America) secures a dominant market presence, driving revenue growth while fulfilling the fundamental goal of expanding patient access to essential medicine.

Biakmawi Phaipi, the Team Captain at Sandoz, coordinates cross-functional collaboration to accelerate the delivery of generic medicines to global markets. Leading internal initiatives, the Team Captain fosters a culture of operational excellence and high-performance teamwork across the organization. This role involves aligning diverse departments with the core mission of improving patient outcomes through accessible healthcare solutions. Biakmawi Phaipi facilitates communication between research, manufacturing, and distribution teams to ensure seamless project execution. By removing operational bottlenecks, the Team Captain drives efficiency in the development of cardiovascular and immunology treatments. The Team Captain monitors project timelines and resource allocation, ensuring that all internal goals align with the strategic objectives of the company. Through proactive leadership, the Team Captain empowers staff to achieve ambitious targets, ultimately strengthening the ability of the firm to meet the evolving needs of patients worldwide.

Elena Morchenko, the Med at Sandoz, oversees the clinical integrity and medical compliance of the generic and biosimilar product pipeline. Directing the medical affairs strategy, the Med ensures that all therapeutic offerings meet rigorous safety and efficacy standards before reaching patients. This role involves constant engagement with regulatory bodies and clinical researchers to validate the quality of oncology and immunology treatments. Elena Morchenko architects the medical communication framework, providing essential data to healthcare providers regarding the benefits of generic alternatives. By maintaining high clinical standards, the Med supports the reputation of the company as a trusted provider of healthcare solutions. The Med evaluates emerging medical research to identify opportunities for portfolio expansion, ensuring that the company remains at the forefront of pharmaceutical innovation. Through meticulous clinical oversight, the Med guarantees that every product manufactured aligns with the commitment to patient health and safety.